Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Saturday, November 7, 2026

Back to the front page

From X

@stockgutter 1 click

SG on X

$ZURA Q3 report looked fine to me. All eyes awaiting H2 readout. Just bought this last week, covered by calls. Options premia were off the charts then and still are quite large (e.g. while the stock was trading 3.36, my net price for the portion I covered with Nov 5C was 2.46. Even less for the portion I covered w Mar 7.5C). I realize readout could occur before Nov expiry and the options reflect the risk of a bad readout. I'm comfortable taking that risk.
@StableBread 1 click

Fajasy on X

My bear, base, and bull cases value Boost Run’s $BRUN stock on year-end 2026 ARR (on the same basis as the multiples of CoreWeave $CRWV, Nebius $NBIS, and $IREN), which $BRUN will report with its Q4 results in March 2027. None of the three cases adds the $160.7M/year from the July order and Cohere, since both start in 2027. The peers’ contracts that start after 2026 aren’t in their year-end ARR either, so they’re priced into the multiples instead. Since the peers’ multiples leave out the debt they’ll take on to reach year-end ARR, I hold $BRUN’s net debt at today’s $244.3M, rather than adding the lease debt from its H2 2026 build. Each case’s value is year-end ARR times the multiple, minus the $244.3M of net debt, divided by the 88.8M fully diluted shares plus any new shares from a stock sale. I start with the $231.4M of ARR from contracts already running, then add (1) the June order’s $69.2M/year if it starts by December 31 and (2) however much of the $99.4M from contracts without disclosed terms is running by then. Bear case ($4.76, -46%) The bear case assumes $BRUN has no new financing to show by its Q3 report, lessors fund 70% of the H2 2026 build instead of 79.5% (below the 72.0% lessors funded in 2025), and the June order’s November 30 start slips into 2027, so 2026 GPU spending stays at the $1.0B low end of management’s range. That implies year-end ARR of $280M, 30% short of the target, a $62.2M stock sale at $8.89/share (7.0M new shares) to cover the funding gap and three months of 2027 payments, and today’s 2.5x, for a value of $4.76/share. I give the bear case about a 20% chance. Base case ($16.17, +82%) The base case assumes $BRUN lands new lease or asset-backed financing by year-end, starts the June order on November 30, and reaches its $400M target without selling stock. That implies $400M of year-end ARR at CoreWeave’s 4.2x, the median of the three peers, for a value of $16.17/share. I use today’s median, since the base case only solves $BRUN’s own financing problem. It assumes no relief on rates or borrowing costs, which would lift the peers’ multiples too. Bull case ($19.78, +122%) The bull case assumes everything in the base case, plus relief on rates and borrowing costs that lifts the peers’ multiples. That implies $400M of year-end ARR at 5.0x, still below Nebius’s 5.9x, for a value of $19.78/share. So the bull case is really a bet on the market, not on anything more from $BRUN. From $8.89/share, you’re risking a $4.13 loss (-46%) in the unlikely bear case for a $10.89 gain (+122%) in the more likely bull case. P.S. These cases use the October 16 close and predate $BRUN’s October 26 release, which says it has closed more than $600M of non-dilutive project financing in 2026.

Investor Letters

All letters

Entravision Q3 Update

Entravision’s Q3 ad-tech revenue reached $177.2 million, up 133% year over year, while total revenue rose 88% to $226.3 million and diluted…

EVC $832M
The Value Road 4 clicks

GREAT DEC-TECTIVE WORK

Diversified Energy reported $255.6 million of “true” nine-month free cash flow, while its $1.8 billion Birch acquisition would shift…

DEC $900M
The Oak Bloke 2 clicks

Problems at Twist Bioscience (TWST)

Twist Bioscience’s $200 rebound followed an Anthropic-linked short squeeze, yet its DNA and protein services face broad competition while…

TWST $8B
Hunterbrook 4 clicks

VSH Earnings Review

Vishay reported record Q3 revenue of $979 million, up 24%, and guided Q4 to about $990 million as rising backlog and margins contrast with…

VSH $3.6B
Cestrian Capital Research 3 clicks

Research Note

Nine Mile Metals is the subject of a research note.

VMSXF $14M
Atrium Research - Equity Research 4 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 109

YouTube 4

Blogs 15

Seeking Alpha 74 of 277

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

359 firms

Sectors

Ordered by how often our editor reaches for them.